25 research outputs found

    Volcanismo jurásico del sector valenciano de la Cordillera Ibérica. Distribución y trama estructural

    Get PDF
    En el sector valenciano de la Cordillera Ibérica se desarrolla durante elJurásico un volcanismo fundamentalmente piroclástico, con emisiones basálticas y traquibasálticas en el Pliensbachiense, Toarciense y Bajociense. La cartografía de los afloramientos permite definir dos alineaciones NW-SE (franja de Caudiel, alineación piroclástica de Alcublas), asi como un área más amplia de traza general NE-SW en las sierras de Javalambre y Camarena. Tal disposicion regional sugiere que las manifesiaciones volcánicas ocurren según dos direcciones principales de fracturación tardihercínica (NW-SE y NE-SW) y aún posiblemente a favor de los puntos de intersección de ambos sistemas estructurales. La dirección NW-SE ejerce el máximo control de la actividad volcánica jurásica, al igual que previamente durante el Triásico superior (línea ofítica de Altura)

    Geoquímica aplicada al medio ambiente

    Get PDF
    In this work it is intended to determinate the different effects that the chemical elements defining the "landscape geochemistry" produce in the environment. These effects, thougt to be positive or negative under human perspective, are due to the physico-chemical behaviour of the element, to their interaction with the environrnent and the final use of these elements by the man. The different methods and techniques applied in geochemical prospecting are presented in order to examine the varied options determined on the defined object. As last target, this work deals with placing the enviromental applied geochemistry as an geochemical prospecting and geoepidemiology and enviromental geochemistry interactiori. Five examples in zones near Barcelona and the isle of Menorca are presented

    Geochemical exploration in the Montseny Mountains (NE Spain)

    Get PDF
    A five year program of systematic multi-element geochemical exploration of the Catalonian Coastal Ranges has been initiated by the Geological Survey of Autonomic Government of Catalonia (Generalitat de Catalunya) and the Department of Geological and Geophysical Exploration (University of Barcelona). This paper reports the first stage results of this regional survey, covering an area of 530 km2 in the Montseny Mountains, NE of Barcelona (Spain). Stream sediments for metals and stream waters for fluoride were chosen because of the regional characteristics. Four target areas for future tactic survey were recognized after the prospect. The most important is a 40 km* zone in the Canoves-Vilamajor area, with high base metal values accompanied by Cd, Ni, Co, As and Sb anomalie

    Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

    Get PDF
    Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

    Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

    Get PDF
    BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

    Geoquímica aplicada al medio ambiente

    No full text
    In this work it is intended to determinate the different effects that the chemical elements defining the "landscape geochemistry" produce in the environment. These effects, thougt to be positive or negative under human perspective, are due to the physico-chemical behaviour of the element, to their interaction with the environrnent and the final use of these elements by the man. The different methods and techniques applied in geochemical prospecting are presented in order to examine the varied options determined on the defined object. As last target, this work deals with placing the enviromental applied geochemistry as an geochemical prospecting and geoepidemiology and enviromental geochemistry interactiori. Five examples in zones near Barcelona and the isle of Menorca are presented

    Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF

    No full text
    Introduction A principal aim of the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) was to document changes in treatment practice for patients with newly diagnosed atrial fibrillation during an era when non-vitamin K antagonist oral anticoagulants (NOACs) were becoming more widely adopted. In these analyses, the key factors which determined the choice between NOACs and vitamin K antagonists (VKAs) are explored

    Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF

    No full text
    Introduction A principal aim of the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) was to document changes in treatment practice for patients with newly diagnosed atrial fibrillation during an era when non-vitamin K antagonist oral anticoagulants (NOACs) were becoming more widely adopted. In these analyses, the key factors which determined the choice between NOACs and vitamin K antagonists (VKAs) are explored

    Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry

    No full text
    Aims Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend a target range of international normalised ratio (INR) of 2.0 - 3.0 for stroke prevention in atrial fibrillation (AF). We analysed the time in this therapeutic range (TTR) of VKAtreated patients with newly diagnosed AF in the ongoing, global, observational registry GARFIELD-AF. Taking TTR as a measure of the quality of patient management, we analysed its relationship with 1-year outcomes, including stroke/systemic embolism (SE), major bleeding, and all-cause mortality
    corecore